Economic information and modeling report
Modeling overview
1 evidence topic · 2 sources
Summary
The economic evidence in this report concerns the disease and comparator treatment pathways. A systematic review reported average metastatic colorectal cancer treatment costs ranging from $12,346 to $293,461 across heterogeneous studies. A separate analysis of 82 participants used a US Medicare payer perspective and reported an incremental cost-effectiveness ratio of US$518,000 per quality-adjusted life-year gained. These figures do not estimate the acquisition cost, cost effectiveness, or budget impact of zanzalintinib.
Zanzalintinib-specific health technology assessment
No evidence found.
Zanzalintinib-specific acquisition price, annual treatment cost, price corridor, cost-effectiveness analysis, and budget-impact results
No evidence found.
Public zanzalintinib-specific economic model
No evidence found.